Barclays PLC Acquires 39,102 Shares of CARGO Therapeutics, Inc. (NASDAQ:CRGX)

Barclays PLC increased its holdings in CARGO Therapeutics, Inc. (NASDAQ:CRGX) by 226.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 56,354 shares of the company’s stock after buying an additional 39,102 shares during the period. Barclays PLC’s holdings in CARGO Therapeutics were worth $1,039,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its stake in CARGO Therapeutics by 437.8% during the third quarter. BNP Paribas Financial Markets now owns 11,438 shares of the company’s stock worth $211,000 after buying an additional 9,311 shares during the period. SG Americas Securities LLC purchased a new position in CARGO Therapeutics during the third quarter worth $234,000. MetLife Investment Management LLC boosted its stake in CARGO Therapeutics by 59.3% during the third quarter. MetLife Investment Management LLC now owns 19,833 shares of the company’s stock worth $366,000 after buying an additional 7,380 shares during the period. Rhumbline Advisers boosted its stake in CARGO Therapeutics by 14.0% during the second quarter. Rhumbline Advisers now owns 30,639 shares of the company’s stock worth $503,000 after buying an additional 3,765 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in CARGO Therapeutics by 11.5% during the second quarter. Bank of New York Mellon Corp now owns 69,171 shares of the company’s stock worth $1,136,000 after buying an additional 7,146 shares during the period. Institutional investors own 93.16% of the company’s stock.

CARGO Therapeutics Stock Performance

Shares of CARGO Therapeutics stock opened at $13.76 on Tuesday. The company has a market capitalization of $633.35 million and a PE ratio of -3.23. The company has a 50-day simple moving average of $17.65 and a two-hundred day simple moving average of $17.81. CARGO Therapeutics, Inc. has a one year low of $12.17 and a one year high of $33.92.

CARGO Therapeutics (NASDAQ:CRGX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.26. On average, equities analysts predict that CARGO Therapeutics, Inc. will post -3.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $33.00 target price on shares of CARGO Therapeutics in a research note on Friday, November 15th. Chardan Capital reissued a “buy” rating and set a $28.00 target price on shares of CARGO Therapeutics in a research note on Wednesday, November 13th. Finally, William Blair assumed coverage on shares of CARGO Therapeutics in a research note on Tuesday, November 26th. They set an “outperform” rating for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $31.80.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.